Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 1374 • 2017 ACR/ARHP Annual Meeting
Flares in Patients with Rheumatoid Arthritis Are Strongly Associated with Worse Clinical Outcomes but Are Difficult to Predict
Katie Bechman¹, L. Tweehuysen², James Galloway³, Andrew P. Cope⁴ and Margaret Ma¹, ¹Academic Rheumatology Department, Kings College London, London, United Kingdom, ²Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ³King's College Hospital, Department of Rheumatology, London, London, United Kingdom, ⁴Academic Department of Rheumatology in the Division of Immunology, Infection and Inflammatory Diseases (DIIID), King's College London, London, Great Britain
Background/Purpose: Disease flares in RA are associated with radiographic progression1 and functional deterioration2. Predicting flare is of direct relevance to clinical practice, particularly in patients…
Abstract Number: 1388 • 2017 ACR/ARHP Annual Meeting
Fatigue Is Strongly Associated with the Patient Global Assessment and May Affect Disease Severity and Clinical Remission in Patients with Rheumatoid Arthritis: A Cross-Sectional Study from IORRA, a Large Observational Cohort of Japanese Rheumatoid Arthritis Patients
Naoki Sugimoto¹, Eiichi Tanaka¹, Eisuke Inoue^1,2, Kumiko Saka¹, Eri Sugano¹, Naohiro Sugitani¹, Moeko Ochiai¹, Yoko Shimizu¹, Rei Yamaguchi¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: Fatigue is a common complaint in patients with rheumatoid arthritis (RA)1. However, its impact on disease activity and clinical remission in patients with RA…
Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Arata Nakajima¹, Masato Sonobe¹, Shinji Taniguchi¹ and Koichi Nakagawa², ¹Orthopaedics, Toho University Sakura Medical Center, Sakura-city, Chiba, Japan, ²Toho University Sakura Medical Center, Sakura-city, Chiba, Japan
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
Abstract Number: 1449 • 2017 ACR/ARHP Annual Meeting
Development of a Predictive Score of Successful TNF Inhibitor Tapering in Patients with Rheumatoid Arthritis Remission
Clothilde Barral¹, David Hajage², Bruno Fautrel³, Pierre Lafforgue¹, Florence Tubach² and Thao Pham¹, ¹Rheumatology, APHM, Aix Marseille Univ, Marseille, France, ²APHP, Pitié Salpêtrière Hospital, Département Biostatistics and Public health, Pharmacoepidémiology center (Cephepi), 75018 75013, Paris, France, Paris, France, ³Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France
Background/Purpose: Tapering trials confirmed the feasibility of TNF inhibitors (TNFi) tapering for a relevant proportion of patients in remission and/or low disease activity. However, there…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 1797 • 2017 ACR/ARHP Annual Meeting
Insights from Treating to Target in Rheumatoid Arthritis at an Academic Medical Center
Malithi Jayasundara¹, Ryan Jessee², Jason Weiner³, Tayseer Haroun⁴, Stephanie Giattino⁵, Atul Kapila⁴, Jenelle Hall⁴, Lisa Carnago⁴ and Lisa Criscione-Schreiber⁶, ¹Rheumatology, Duke University, Durham, NC, ²Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC, ³Department of Medicine, Division of Rheumatology and Immunology, Duke University Medical Center, Durham, NC, ⁴Duke University, Durham, NC, ⁵Rheumatology, Duke University Medical Center, Durham, NC, ⁶Internal Medicine, Duke University Medical Center, Durham, NC
Background/Purpose: Current RA guidelines recommend treating to a target of remission or low disease activity (RM/LDA) state. In a prior quality improvement (QI) project, our…
Abstract Number: 2434 • 2017 ACR/ARHP Annual Meeting
Baseline Expressions of Cellular microRNA-31 and microRNA-10a Predict Remission and Low Disease Activity in Patients with Early Rheumatoid Arthritis after Six and Twelve Months of Therapy
Veronika Hruskova^1,2, Klara Prajzlerova³, Martin Komarc⁴, Lucia Vernerova¹, Herman F Mann³, Maria Filkova³, Karel Pavelka³, Jiri Vencovsky³ and Ladislav Senolt³, ¹Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, ²Faculty of Science, Charles University, Prague, Czech Republic, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ⁴Department of Anthropometrics and Methodology, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: MicroRNAs (miRNAs) post-transcriptionally regulate gene expression by targeting messenger RNAs. The expression of miRNAs was demonstrated to differ between patients with rheumatoid arthritis (RA)…
Abstract Number: 631 • 2016 ACR/ARHP Annual Meeting
Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender
Alfredomaria Lurati¹, Magda Scarpellini², Katia Angela re³, Mariagrazia Marrazza³, Daniela Mazzocchi³ and Antonella Laria⁴, ¹Fornaroli Hospital Rheumatology Unit Magenta Italy, Magenta, Italy, ²Rheumatology Unit, Ospedale Fornaroli, Magenta, Italy, ³Fornaroli Hospital, Rheumatology Unit, MAgenta, Italy, ⁴Fornaroli Hospital, Rheumatology Unit, Magenta, Italy
Biologic free remission rate with etanercept in rheumatoid arthritis: a potential role of gender A.M. Lurati and A. Laria, D. Mazzocchi, K.A. Re, M. Marrazza,…
Abstract Number: 1417 • 2016 ACR/ARHP Annual Meeting
Back to Feeling Normal Again: Patients with Rheumatoid Arthritis in Remission
Linda Rasch¹, Maarten Boers^2,3, Willem F. Lems^1,2, Samina Turk⁴, Dirkjan van Schaardenburg^2,5, Tessa Sanderson⁶, Sarah Hewlett⁶ and Lilian van Tuyl¹, ¹Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁵Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁶Nursing and Midwifery, University of the West of England, Bristol, United Kingdom, Bristol, United Kingdom
Background/Purpose: The American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) definition of remission in rheumatoid arthritis (RA) [1] lacks information on patient perceived remission [2].…
Abstract Number: 1995 • 2016 ACR/ARHP Annual Meeting
Smoking Is Associated with Unfavorable Flare/ Remission Pattern in Patients with Rheumatoid Arthritis
Shafay Raheel¹, Cynthia S. Crowson², Eric L. Matteson¹ and Elena Myasoedova¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Smoking is well recognized as a risk factor for rheumatoid arthritis (RA), and determinant of RA disease activity, severity, response to therapy, and possibly…
Abstract Number: 2227 • 2016 ACR/ARHP Annual Meeting
Sustained Remission and Relapse Rate after Non-Conventional DMARD Withdrawal in Patients with Rheumatoid Arthritis
Andrea Ramirez-Gomez¹, Aldo Barajas-Ochoa¹, Jose Juan Castaneda-Sanchez¹, Jose Dionisio Castillo-Ortiz¹, Jorge M. Sanchez-Gonzalez² and Cesar Ramos-Remus², ¹Unidad de Investigacion en Enfermedades Cronico-Degenerativas, Guadalajara, Mexico, ²Vicerrectoria Academica, Universidad Autonoma de Guadalajara, Guadalajara, Mexico
Background/Purpose: The treatment of rheumatoid arthritis (RA) has evolved continuously. The introduction of non-conventional DMARDs, which include biologic and targeted synthetic DMARDs (tsDMARDs), has been…
Abstract Number: 2462 • 2016 ACR/ARHP Annual Meeting
Higher Number of Tender Than Swollen Joint Count Is Associated to Higher Patient Reported Outcomes and Composite Scores As Well As Reduced Probability of Obtaining Remission: Results from a One-Year Follow-up Study of Established RA Patients Starting Bdmards
Hilde Berner Hammer^1,2, Till Uhlig¹, Tore K. Kvien^1,2 and Jon Lampa³, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Dep of Medicine, Rheumatology unit, Karolinska Institute, Karolinska Institute, Stockholm, Sweden
Background/Purpose: The swollen and tender joint count is included in composite scores (DAS28, CDAI, SDAI, ACR/EULAR Boolean remission). Low swollen/tender joint ratio (STR) has been…
Abstract Number: 2465 • 2016 ACR/ARHP Annual Meeting
Discordance Between Tender and Swollen Joint Count and Patient’s and Evaluator’s Global Assessment May Reduce Likelihood of Remission in Rheumatoid Arthritis
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde B Hammer³, Eirik K Kristianslund¹, Glenn Haugeberg^4,5 and Tore K Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Chronification of pain and development of central sensitization and conditioned pain modulation can lead to disconnection between tender and swollen joint count, which may…
Abstract Number: 2466 • 2016 ACR/ARHP Annual Meeting
Remission According to RAPID3 (routine assessment of patient index data 3) in Patients with Rheumatoid Arthritis: A Cross-Sectional 3 Center Study from Routine Care
Isabel Castrejón¹, Martin J. Bergman², Kathryn Gibson^3,4, Yusuf Yazici⁵, Joel Block⁶ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology, Taylor Hospital, Ridley Park, PA, ³Liverpool Hospital, Sydney, Sydney, Australia, ⁴Ingham Research Institute, Liverpool, Australia, ⁵Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Remission rates in patients with rheumatoid arthritis (RA) according to RAPID3 (routine assessment of patient index data) are reported at 25% in France1 and…
Abstract Number: 2476 • 2016 ACR/ARHP Annual Meeting
Performance of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) Appears to be Better Than Gold Standard Disease Assessment Score (DAS-28 CRP)
Pooja Dhaon¹, Siddharth K. Das², Ragini Srivastava³ and Urmila Dhakad⁴, ¹Medicine, Hind Institute of Medical Sciences, Uttar Pradesh, India., Barabanki, India, ²Rheumatology, Prof. and Head, Rheumatology, K.G. Medical University, Lucknow, Lucknow, India, ³Rheumatology, Senior Research Officer, Rheumatology, K.G. Medical University, Lucknow, India, Lucknow, India, ⁴Rheumatology, Asst Professor, K.G. Medical University, Lucknow, India, Lucknow, India
Background/Purpose : To compare the performance of DAS-28 CRP, CDAI and SDAI composite measures to assess status of patients with Rheumatoid Arthritis on Methotrexate, versus…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].